Summit Therapeutics Inc. develops oncology medicines led by ivonescimab, an investigational PD-1 / VEGF bispecific antibody in-licensed from Akeso. The company reports clinical and operational updates for ivonescimab programs in non-small cell lung cancer and colorectal cancer, including multiregional Phase III studies and data presentations from HARMONi trials.
Recurring Summit Therapeutics news also covers financial results, regulatory updates tied to the accepted Biologics License Application for ivonescimab in EGFR-mutated non-squamous NSCLC after tyrosine kinase inhibitor therapy, clinical trial collaborations, and equity-compensation actions under Nasdaq rules. Summit holds development and commercialization rights for ivonescimab across North America, South America, Europe, the Middle East, Africa, and Japan.
Summit Therapeutics (SMMT) closed AstraZeneca’s (AZN) $2.0 billion equity investment to support development of its investigational cancer therapy ivonescimab.
AstraZeneca purchased approximately 108,955 preferred shares, convertible into Summit common shares at a 1:1,000 ratio. The implied common share price of $18.36 represents a premium to the closing trading price on the investment’s announcement day. Summit plans to use the funds to accelerate development across solid tumors, including combinations with sonesitatug vedotin and Datroway, drugs that deliver chemotherapy through antibodies. The FDA accepted Summit’s ivonescimab marketing application for filing in January 2026, with a target decision date of November 14, 2026.
Daiichi Sankyo (4568) and AstraZeneca (AZN) entered a clinical trial collaboration with Summit Therapeutics (SMMT) to evaluate Datroway combined with ivonescimab.
The collaboration covers multiple tumor types, including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative breast cancer, testing the combination as an initial treatment. Datroway is an antibody-drug conjugate, which links an antibody to a cancer-killing drug, jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
Each company will supply its respective compound and contribute to trial costs. AstraZeneca or Daiichi Sankyo will sponsor the planned combination trials. Each company will retain development and commercial rights to its respective medicine. The agreement establishes planned combination studies; it does not report results from them.
Summit Therapeutics (SMMT) announced a clinical trial collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab combinations. The agreement covers ivonescimab with Datroway (datopotamab deruxtecan), an antibody linked to a cancer drug that targets TROP2. The companies intend to evaluate the combination across multiple solid tumor settings, including breast and lung cancer, starting with a Phase III trial in first-line triple-negative breast cancer.
AstraZeneca or Daiichi Sankyo will sponsor the planned combination trials. Each company will supply its respective therapy and contribute to trial costs, while retaining development and commercial rights to its own medicine. Ivonescimab remains investigational and is not approved in Summit’s licensed territories, including the United States and Europe.
Summit Therapeutics (SMMT) agreed to a $2 billion convertible preferred-share investment from AstraZeneca (AZN) alongside a signed cancer-trial collaboration.
AstraZeneca will buy approximately 108,955 preferred shares, convertible into Summit common stock at a 1:1,000 ratio. The conversion implies $18.36 per common share, a premium to the closing trading price and 10% above the prior week’s five-day volume-weighted average. Closing is expected by the end of the announcement week, subject to customary conditions.
The signed collaboration will test Summit’s investigational ivonescimab with AstraZeneca’s sonesitatug vedotin in gastrointestinal cancers. Both companies will supply their drugs and share study costs. A separate, non-binding memorandum outlines intended trials combining ivonescimab with other AstraZeneca cancer medicines, including antibody-drug conjugates.
Summit Therapeutics (SMMT)/b) highlighted that Phase III HARMONi-GI1 data for ivonescimab plus chemotherapy in first-line advanced biliary tract cancer (BTC) will be featured in the Presidential Symposium II at ESMO 2026 on October 25, 2026, in Madrid.The Akeso-sponsored, randomized, double-blinded study conducted in China compared ivonescimab plus chemotherapy versus durvalumab plus chemotherapy. At a prespecified interim analysis, the ivonescimab regimen achieved statistically significant and clinically meaningful superiority in the primary endpoint of overall survival, and also met key secondary endpoints of progression-free survival and objective response rate. Summit describes HARMONi-GI1 as the first known Phase III BTC trial to show overall survival superiority versus an anti‑PD‑(L)1 plus chemotherapy regimen and the first Phase III ivonescimab readout beyond NSCLC.
Ivonescimab (SMT112 in Summit territories, AK112 elsewhere) is approved in China for NSCLC but remains investigational and unapproved in Summit’s territories, where it is being studied across multiple Phase III and Phase II/III trials, including NSCLC, colorectal cancer, biliary tract cancer, and urothelial carcinoma.
Summit Therapeutics (SMMT)/b) reported updated overall survival (OS) data from the global Phase III HARMONi trial of ivonescimab plus platinum-doublet chemotherapy in EGFR-mutated NSCLC, presented at WCLC 2026.The June 2026 global intention-to-treat analysis showed an OS hazard ratio of 0.76 (95% CI: 0.61–0.95; nominal p=0.0151) versus placebo plus chemotherapy, with median OS of 16.8 vs 14.0 months, unchanged from earlier cuts. Western patients achieved an OS hazard ratio of 0.76 (95% CI: 0.52–1.10) and median OS of 17.5 vs 14.0 months at 23.2 months’ median follow-up, aligning with Asian results. No new safety signals were seen and the safety profile remained acceptable and manageable.
In Akeso’s China-only Phase III HARMONi-2, ivonescimab monotherapy improved OS versus pembrolizumab with a hazard ratio of 0.73 (95% CI: 0.57–0.95; p=0.009) and median OS of 30.8 vs 22.6 months. Summit’s BLA for ivonescimab in the HARMONi setting has a U.S. FDA PDUFA goal date of November 14, 2026.
Summit Therapeutics (SMMT) highlighted updated Phase III HARMONi-2 results showing ivonescimab reduced death risk by 27% versus pembrolizumab.
The China-based, randomized, double-blind study in PD-L1-positive advanced NSCLC (n=398) reported median overall survival of 30.8 months with ivonescimab versus 22.6 months with pembrolizumab, with a stratified OS hazard ratio of 0.73 (95% CI: 0.57–0.95; p=0.009) after 36 months median follow-up. In the PD-L1 ≥50% subgroup, the hazard ratio was 0.58 (95% CI: 0.38–0.89). Serious treatment-related adverse events occurred in 29.9% of ivonescimab patients versus 21.6% for pembrolizumab, while discontinuations due to treatment-related events were 4.1% and 5.0%, respectively.
Ivonescimab is approved and commercially available in China and remains investigational in Summit’s territories; a separate BLA based on the HARMONi study has been accepted by the FDA with a goal PDUFA date of November 14, 2026. Summit is also running the global Phase III HARMONi-7 trial in PD-L1 high-expressing metastatic NSCLC.
Summit Therapeutics (SMMT)/b) highlighted that partner Akeso’s Phase III HARMONi-2 trial showed ivonescimab monotherapy achieved a statistically significant overall survival benefit versus pembrolizumab monotherapy in PD-L1-positive advanced NSCLC.In this randomized, double-blind study conducted in China, ivonescimab had previously met the primary endpoint of progression-free survival (PFS) by independent radiologic review, with a hazard ratio of 0.51 (95% CI: 0.38–0.69; p<0.0001). Akeso obtained Chinese marketing authorization for ivonescimab in April 2025 based on HARMONi-2, and the drug has been commercially available in China since an initial approval in May 2024.
Ivonescimab (SMT112 in Summit territories) is a tetravalent, bispecific anti-PD-1/anti-VEGF antibody being studied in at least 16 Phase III trials worldwide, including five Summit-sponsored global studies. A separate Summit HARMONi Phase III NSCLC trial supported a BLA that the FDA accepted in January 2026, with a goal PDUFA decision date of November 14, 2026. Ivonescimab remains investigational and unapproved in Summit’s licensed regions, including the United States and Europe.
Summit Therapeutics (NASDAQ: SMMT) reported that partner Akeso announced positive topline results from the randomized Phase III HARMONi-GI1 trial in first-line advanced biliary tract cancer (BTC). In this single-region, multi-center study conducted in China, ivonescimab plus chemotherapy achieved statistically significant and clinically meaningful superiority in the primary endpoint of overall survival versus durvalumab plus chemotherapy, at a prespecified interim analysis.
The trial also met key secondary endpoints of progression-free survival and objective response rate. Detailed safety and efficacy data are expected at a future medical congress and in a peer-reviewed journal. Ivonescimab (SMT112 in Summit territories) is a bispecific PD-1/VEGF antibody engineered by Akeso, with over 4,000 patients treated in clinical studies and more than 70,000 in commercial use in China. Ivonescimab is approved in China for non-small cell lung cancer but remains investigational and unapproved in Summit’s territories, where a separate HARMONi-based BLA for NSCLC is under FDA review with a PDUFA date of November 14, 2026.
Summit Therapeutics (NASDAQ: SMMT) reported that primary analysis results from the global Phase III HARMONi trial of ivonescimab plus platinum-doublet chemotherapy in EGFR-mutated, locally advanced or metastatic non-squamous NSCLC after third-generation EGFR TKI progression were published in The Lancet Oncology.
According to Summit, ivonescimab plus chemotherapy achieved median progression-free survival of 6.8 months versus 4.4 months with placebo plus chemotherapy, with a hazard ratio of 0.52 (95% CI: 0.41–0.66; p<0.0001). Overall survival showed a positive trend but was not statistically significant at primary analysis. Treatment-related grade 3–5 hemorrhage occurred in <1% of ivonescimab-treated patients. An updated analysis showed a continued positive OS trend, including a hazard ratio of 0.76 in western patients. Ivonescimab is under FDA review via a BLA for this indication with a PDUFA target date of November 14, 2026.